 WALTHAM, Mass., May 14, 2021 GLOBE NEWSWIRE -- Eloxx Pharmaceuticals, Inc. the Company Nasdaq: ELOX, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the pricing of an underwritten public offering of 33,333,334 shares of common stock at a public offering price of 1.35 per share. In addition, the Company expects to grant the underwriters a 30-day option to purchase an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. 